Skip to content
POM-V Prescription Required Companion Animal

Inflacam 2.5 mg Chewable Tablets for Dogs

Active ingredient: Meloxicam

Form

Chewable

Species

Dogs

Manufacturer

Chanelle Pharmaceuticals Manufacturing Ltd

VMD MA No.

08749/5012

What it's used for

Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery. Allev...

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Meloxicam

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Inflacam 2.5 mg Chewable Tablets for Dogs — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Alleviation of mild to moderate post-operative pain and inflammation following
surgical procedures in cats, e.g. orthopaedic and soft tissue surgery.
Alleviation of inflammation and pain in acute and chronic musculo-skeletal disorders
in cats.
Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day.
Treatment is to be continued once daily by oral administration (at 24-hour intervals) at
a maintenance dose of 0.1 mg meloxicam/kg body weight.
Each chewable tablet contains 2.5 mg meloxicam, which corresponds to the daily
maintenance dose for a 25 kg body weight dog.
Each chewable tablet can be halved for accurate dosing according to the individual
body weight of the dog.
To ensure a correct dosage, body weight should be determined as accurately as
possible.
The use of suitably calibrated measuring equipment is recommended.
The veterinary medicinal products can be administered with or without food, are
flavoured and are taken by most dogs voluntarily.
Dose scheme for the maintenance dose:
Body weight (kg)
Number of 2.5 mg chewable
tablets
mg/kg
20.1–25 10.12–0.125.1–35 1½0.15–0.135.1–50 20.14–0.1
For dogs weighing between 4 and 20 kg, the use of Inflacam 1 mg chewable tablets
for dogs are recommended.
The use of Inflacam oral suspension for dogs may be considered for an even more
precise dosing. For dogs weighing less than 4 kg, the use of Inflacam oral suspension
for dogs is recommended.
A clinical response is normally seen within 3–4 days. Treatment should be
discontinued after 10 days if no clinical improvement is apparent.
Do not use in pregnant or lactating animals.
Do not use in dogs suffering from gastrointestinal disorders such as irritation and
haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Do not use in case of hypersensitivity to the active substance or to any of the
excipients.
Do not use in dogs less than 6 weeks of age or less than 4 kg body weight.
Dogs:
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Appetite loss, Lethargy
Vomiting, Diarrhoea, Blood in faeces
,
Haemorrhagic diarrhoea, Haematemesis,
Gastric ulcer, Small intestine ulcer, Large
intestine ulcer
Elevated liver enzymes
Renal failure
occult
These side effects occur generally within the first treatment week and are in most cases
transient and disappear following termination of the treatment but in very rare cases
may be serious or fatal.
If adverse reactions occur, treatment should be discontinued and the advice of a
veterinarian should be sought.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See also the package leaflet for
respective contact details.
None.

Special precautions for safe use in the target species:
This product for dogs should not be used in cats as it is not suitable for use in this
species.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a
potential risk of increased renal toxicity.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs)
should avoid contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances
with high protein binding may compete for binding and thus lead to toxic effects. The
veterinary medicinal product must not be administered in conjunction with other
NSAIDs or glucocorticosteroids.
Pre-treatment with anti-inflammatory substances may result in additional or increased
adverse effects and accordingly a treatment-free period with such veterinary medicinal
products should be observed for at least 24 hours before commencement of treatment.
The treatment-free period should however take into account the pharmacokinetic
properties of the veterinary medicinal products previously used.
This veterinary medicinal product does not require any special storage conditions.
Any unused half tablet should be discarded.
For dogs weighing between 4 and 20 kg, the use of Inflacam 1 mg chewable tablets
for dogs are recommended.
The use of Inflacam oral suspension for dogs may be considered for an even more
precise dosing. For dogs weighing less than 4 kg, the use of Inflacam oral suspension
for dogs is recommended.
A clinical response is normally seen within 3–4 days. Treatment should be
discontinued after 10 days if no clinical improvement is apparent.
3.10 Symptoms of overdose (and where applicable, emergency procedures and
antidotes)
In case of overdose, symptomatic treatment should be initiated.
3.11 Special restrictions for use and special conditions for use, including
restrictions on the use of antimicrobial and antiparasitic veterinary
medicinal products in order to limit the risk of development of resistance
Not applicable.
3.12 Withdrawal periods
Not applicable.
4.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.